| Today’s Big NewsMar 25, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By Nick Paul Taylor Novo Nordisk is pumping up its heart failure plans. The drugmaker, dripping with its GLP-1 billions, has agreed to buy Cardior Pharmaceuticals and its midphase prospect in a deal that could top out above 1 billion euros ($1.1 billion). |
|
|
|
By James Waldron Regeneron may have gotten ahead of itself with the early filing of bispecific antibody odronextamab to regulators. In a move that might not surprise keen FDA watchers, the agency has issued two complete response letters over the timelines of ongoing phase 3 confirmatory trials for the drug. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Annalee Armstrong AbbVie has grabbed a wrench to add on some new autoimmune disease options to its pipeline via the acquisition of Landos Biopharma. The deal values the oral therapeutic-focused biotech at $137.5 million. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
By Helen Floersh Theratechnologies is winding down its preclinical oncology research program in an effort to become profitable and focus on its commercial business. The biotech will use what it has learned from the work conducted so far to find an outside collaborator for further R&D. |
By James Waldron Spanish pharma Ferrer is following in Big Pharma’s footsteps by targeting the AI-powered neuroscience R&D work of Verge Genomics. |
By Gabrielle Masson Astria Therapeutics is planning a phase 3 launch for its star monoclonal antibody after early data demonstrated a favorable safety profile and reduction in attack rates of a rare immune disorder. |
By Eric Sagonowsky Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S. officials are pressing the company to pay royalties linked to the commercialization of its lucrative Pfizer-partnered COVID-19 vaccine. |
By Conor Hale Researchers at the University of Washington's Baker Lab have shown that a generative AI program can help draw up atomically accurate antibodies from scratch—including those capable of binding to the proteins found in COVID-19, RSV and influenza. |
By Heather Landi The Peterson Health Technology Institute's analysis assessed whether digital diabetes solutions improve users' health outcomes over "usual care." "The digital health industry is maturing and as it matures, it's very important that we raise the bar on expectations and evidence," Caroline Pearson, executive director of the PHTI. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
Thursday, March 28, 2024 | 11am ET / 8am PT Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Join us to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. Register now. 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
